FLAVOMYCIN® 40, 80
(flavophospholipol)

COMPOSITION
Flavomycin 40 Flavomycin 80
Flavophospholipol 4 g 8 g
Excipients up to 100 g up to 100 g
Produced by fermentation of Streptomyces ghanaensis (DSM 12218).

PHARMACOLOGICAL ACTION
The spectrum of activity covers economically important microorganisms which compete with the host animal for nutrients. Flavomycin inhibits their reproduction by intervening in the biosynthesis of murein, the structural substance of their cell walls. Specifically, the enzyme glyconsyltransferase, that plays an essential role in the synthesis of the cell wall of Gram-positive bacteria, cannot distinguish between flavophospholipol and the natural murein compound. This prevents murein synthesis from taking place. Damage to the murein layer causes cells to burst. However, the desirable lactobacilli and bifidobacteria are unharmed. Flavomycin is one of the most active substances inhibiting murein biosynthesis and is therefore effective in very low doses. An antimicrobial with this mode of action is particularly suitable as a feed additive, as animal cells have no comparable vulnerable structure. This results in the extra-ordinarily high efficacy of and tolerability to Flavomycin.

INDICATIONS
Flavomycin is a performance enhancer for use in pigs, poultry, cattle, rabbits, and aquatic species. Flavomycin allows for the early establishment of normal gut microflora by sparing beneficial lactic acid producing bacteria. Through its sparing effect on the beneficial intestinal microflora, Flavomycin has been proven to be effective in reducing the shedding and infection rates of several harmful intestinal bacteria, such as Salmonella spp., Clostridium and E. coli. Due to its effect on pathogenic bacteria, Flavomycin contributes to a thinning of the intestinal wall, which leads to a better absorption of nutrients and specifically pigments, an improvement of litter quality, provides support of animals during stress situations, e.g., heat stress, etc. As no other member of the same antibiotic class, the phosphoglycolipids, has ever been developed for therapeutical use in humans or animals, Flavomycin poses no risk of increasing the selection for antibiotic resistance in humans. Continuous research, dating back to the 1970's, reveals that Flavomycin actually has the potential to reduce antibiotic resistance.

CONTRAINDICATIONS
Not established.

MODE OF ADMINISTRATION
Orally, following good homogenization with feed. In order to reach uniform homogenization with feed, it is recommended to mix the measured quantity of Flavomycin (calculated on the basis of the prescribed dose) on stages in the following order: up to 10 kg feed; up to 100 kg feed; and up to 1000 kg feed.

TARGET SPECIES
Chickens, turkeys, pigs, rabbits, fish and shrimp, cattle.

SIDE EFFECTS
Not established.

WITHDRAWAL PERIOD
Zero (0) days.
As Flavomycin is not absorbed from the digestive tract, no residues are found in blood or tissues.

SHELF LIFE
Two (2) years from the date of manufacture.

FURTHER INFORMATION
The product is stable under all practical pelleting and expanding conditions